1. NDTMS: community combined review forms

    Combined Review Forms (CRF) for community treatment services to use for Core Dataset P (CDS-P), from April 2020 onwards.

  2. NDTMS: secure setting outcomes forms

    Outcome monitoring forms for use by secure setting from April 2020 for core dataset P.

See more services in this topic

Guidance and regulation

  1. Controlled drugs list
  2. Drug misuse and dependence: UK guidelines on clinical management
  3. Precursor chemical licensing
  4. NDTMS: reference data
  5. Safeguarding children affected by parental alcohol and drug use
See more guidance and regulation in this topic

News and communications

  1. Letter from the ACMD to the Home Secretary: GHB, GBL, and related compounds
  2. Call for evidence: barriers to research with controlled drugs
  3. Advice on Epidyolex
  4. Date set for UK-wide summit in Glasgow on tackling drug misuse
See more news and communications in this topic

Research and statistics

  1. Substance misuse treatment in secure settings: 2018 to 2019
  2. Shooting Up: infections among people who inject drugs in the UK
  3. Substance misuse treatment for young people: statistics 2018 to 2019
  4. Substance misuse treatment for adults: statistics 2018 to 2019
  5. Review of Psychoactive Substances Act 2016: ACMD contribution
See more research and statistics in this topic

Policy papers and consultations

  1. NDTMS annual reports and methodology: proposed changes
  2. NDTMS criminal justice intervention teams dataset: proposed changes
  3. ACMD ageing cohort of drug users report: government response
  4. Drug related harms in homeless populations: government response
  5. Drugs policy and medicinal cannabis report: government response
See more policy papers and consultations in this topic

Transparency and freedom of information releases

  1. Standard Operating Procedure for using evidence in ACMD reports
  2. Commissioning impact on drug treatment
  3. Drug strategy 2016: development review
  4. Psychoactive Substances Bill: evaluation review
  5. Methiopropamine: a review of the evidence of use and harm
See more transparency and freedom of information releases in this topic